Bendectin and birth defects: hopefully, the final chapter.
Brent
Robert
R
Jefferson Medical College, Philadelphia, Pennsylvania, USA. rbrent@nemours.org
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000209:etiology*; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000818:Animals; D000932:Antiemetics / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016022:Case-Control Studies; D004025:Dicyclomine; D004319:Doxylamine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D017277:Drug Approval; D004338:Drug Combinations; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D016365:Liability, Legal; D009325:Nausea / Q000188:drug therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011736:Pyridoxine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012449:Safety; D014481:United States; D014486:United States Food and Drug Administration; D014839:Vomiting / Q000188:drug therapy
D000932:Antiemetics; D004338:Drug Combinations; C004454:dicyclomine, doxylamine, pyridoxine drug combination; D004025:Dicyclomine; D004319:Doxylamine; D011736:Pyridoxine